Direxion Daily Semicondct Bull 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

VS TR -1x Short VIX Futures ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

Direxion Daily Technology Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X ETF

Guggenheim Solar ETF

Direxion Daily Financial Bull 3X ETF

Bank Of Montreal

ProShares UltraPro Dow30

VS TR 2x Long VIX Futures ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares Ultra VIX Short-Term Futures

ProShares Ultra Bloomberg Natural Gas

MicroSectors Gold Miners 3X Leveraged ETN

Direxion Daily S&P Biotech Bear 3X ETF

Direxion Technology Bear 3X Shares

Direxion Financial Bear 3X Shar

Direxion Daily Gold Miners Bull 3X ETF

QuantumScape Corporation Class A Common Stock

Oklo Inc.

Reddit Inc. Class A Common Stock

Uber Technologies Inc. Common Stock

Gray Television Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

Carnival Corporation Common Stock

Ciena Corporation Common Stock

Snap Inc. Class A Common Stock

KKR & Co. Inc. Common Stock

FedEx Corporation Common Stock

AgEagle Aerial Systems Inc. Common Stock

Alamos Gold Inc. Class A Common Shares

Occidental Petroleum Corporation Common Stock

Civitas Resources Inc. Common Stock

Gold Fields Limited American Depositary Shares

Noble Corporation plc A Ordinary Shares

Exxon Mobil Corporation Common Stock

United Microelectronics Corporation (NEW) Common Stock

Raytheon Technologies Corporation Common Stock

Click here to get full coverage on The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SPCE, OCGN and CRMD - ACCESS Newswire

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SPCE, OCGN and CRMD  ACCESS Newswire

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SPCE, OCGN and CRMD - ACCESS Newswire

Click here to get full coverage on Chardan Capital Maintains Buy Rating for Ocugen (OCGN) | OCGN St - GuruFocus

Chardan Capital Maintains Buy Rating for Ocugen (OCGN) | OCGN St  GuruFocus

Chardan Capital Maintains Buy Rating for Ocugen (OCGN) | OCGN St - GuruFocus

Click here to get full coverage on Carisma Therapeutics and OrthoCellix Enter into Definitive - GlobeNewswire

Carisma Therapeutics and OrthoCellix Enter into Definitive  GlobeNewswire

Carisma Therapeutics and OrthoCellix Enter into Definitive - GlobeNewswire

Click here to get full coverage on Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1? - Yahoo Finance

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1?  Yahoo Finance

Is Ocugen Inc. (NASDAQ:OCGN) the Best Penny Stock to Invest in Under $1? - Yahoo Finance

Click here to get full coverage on OCUGEN Earnings Preview: Recent $OCGN Insider Trading, Hedge Fund Activity, and More - Nasdaq

OCUGEN Earnings Preview: Recent $OCGN Insider Trading, Hedge Fund Activity, and More  Nasdaq

OCUGEN Earnings Preview: Recent $OCGN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Click here to get full coverage on Ocugen Announces Merger with Carisma Therapeutics - TipRanks

Ocugen Announces Merger with Carisma Therapeutics  TipRanks

Ocugen Announces Merger with Carisma Therapeutics - TipRanks

Click here to get full coverage on Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha

Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN)  Seeking Alpha

Ocugen: Three Potential Gene-Therapy Filings By 2028 (NASDAQ:OCGN) - Seeking Alpha

Click here to get full coverage on Ocugen (OCGN) Receives Buy Rating Reiteration from HC Wainwright - GuruFocus

Ocugen (OCGN) Receives Buy Rating Reiteration from HC Wainwright  GuruFocus

Ocugen (OCGN) Receives Buy Rating Reiteration from HC Wainwright - GuruFocus

Click here to get full coverage on Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease - Ocugen

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease  Ocugen

Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease - Ocugen

Click here to get full coverage on Ocugen Provides Business Update with First Quarter 2025 Financial Results - Stock Titan

Ocugen Provides Business Update with First Quarter 2025 Financial Results  Stock Titan

Ocugen Provides Business Update with First Quarter 2025 Financial Results - Stock Titan

Click here to get full coverage on Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... - Yahoo Finance

Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ...  Yahoo Finance

Ocugen Inc (OCGN) Q1 2025 Earnings Call Highlights: Strategic Advances in Gene Therapy Amid ... - Yahoo Finance

Click here to get full coverage on The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OCGN, ATHA and DIDI - ACCESS Newswire

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OCGN, ATHA and DIDI  ACCESS Newswire

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of OCGN, ATHA and DIDI - ACCESS Newswire

Click here to get full coverage on OCUGEN Earnings Results: $OCGN Reports Quarterly Earnings - Nasdaq

OCUGEN Earnings Results: $OCGN Reports Quarterly Earnings  Nasdaq

OCUGEN Earnings Results: $OCGN Reports Quarterly Earnings - Nasdaq

Click here to get full coverage on Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan

Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties  Stock Titan

Ocugen's Blindness Gene Therapy Lands Major Korean Deal: $11M Upfront, 25% Royalties - Stock Titan

Click here to get full coverage on Ocugen’s (OCGN) Stock Has Surged 195% on Promising Gene Therapy Treatment - Nasdaq

Ocugen’s (OCGN) Stock Has Surged 195% on Promising Gene Therapy Treatment  Nasdaq

Ocugen’s (OCGN) Stock Has Surged 195% on Promising Gene Therapy Treatment - Nasdaq

Click here to get full coverage on Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance

Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs  Yahoo Finance

Ocugen Inc (OCGN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising Costs - Yahoo Finance

Click here to get full coverage on Gene Therapy Pioneer Ocugen Sets Q1 2025 Earnings Call to Reveal Blindness Treatment Progress - Stock Titan

Gene Therapy Pioneer Ocugen Sets Q1 2025 Earnings Call to Reveal Blindness Treatment Progress  Stock Titan

Gene Therapy Pioneer Ocugen Sets Q1 2025 Earnings Call to Reveal Blindness Treatment Progress - Stock Titan

Click here to get full coverage on $OCGN stock is up 13% today. Here's what we see in our data. - Nasdaq

$OCGN stock is up 13% today. Here's what we see in our data.  Nasdaq

$OCGN stock is up 13% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan

Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal  Stock Titan

Ocugen Showcases Breakthrough Blindness Gene Therapy Platform at BIO 2025 After Korean Partnership Deal - Stock Titan

Click here to get full coverage on Revolutionary Gene Therapy for Blindness: Ocugen Reveals Commercialization Strategy - Stock Titan

Revolutionary Gene Therapy for Blindness: Ocugen Reveals Commercialization Strategy  Stock Titan

Revolutionary Gene Therapy for Blindness: Ocugen Reveals Commercialization Strategy - Stock Titan

Click here to get full coverage on Revolutionary Gene Therapy Platform: Ocugen Presents Phase 3 Trial Results for Multiple Eye Diseases - Stock Titan

Revolutionary Gene Therapy Platform: Ocugen Presents Phase 3 Trial Results for Multiple Eye Diseases  Stock Titan

Revolutionary Gene Therapy Platform: Ocugen Presents Phase 3 Trial Results for Multiple Eye Diseases - Stock Titan

Click here to get full coverage on Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | OCGN Stock News - GuruFocus

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | OCGN Stock News  GuruFocus

Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | OCGN Stock News - GuruFocus

Click here to get full coverage on OCGN stock touches 52-week low at $0.52 amid market challenges - Investing.com

OCGN stock touches 52-week low at $0.52 amid market challenges  Investing.com

OCGN stock touches 52-week low at $0.52 amid market challenges - Investing.com

Click here to get full coverage on Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha

Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN)  Seeking Alpha

Ocugen gets FDA nod to begin mid-stage study of OCU410ST (OCGN) - Seeking Alpha

Click here to get full coverage on Breakthrough: FDA Green-Lights Ocugen's Gene Therapy Trial After 48% Disease Slowdown in Phase 1 - Stock Titan

Breakthrough: FDA Green-Lights Ocugen's Gene Therapy Trial After 48% Disease Slowdown in Phase 1  Stock Titan

Breakthrough: FDA Green-Lights Ocugen's Gene Therapy Trial After 48% Disease Slowdown in Phase 1 - Stock Titan

Click here to get full coverage on Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga

Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial  Benzinga

Ocugen (OCGN) Stock Soars On FDA Clearance For Pivotal Stargardt Disease Trial - Benzinga

Click here to get full coverage on Ocugen Provides Business Update with First Quarter 2025 Financial Results - GlobeNewswire

Ocugen Provides Business Update with First Quarter 2025 Financial Results  GlobeNewswire

Ocugen Provides Business Update with First Quarter 2025 Financial Results - GlobeNewswire

Click here to get full coverage on Ocugen (OCGN) Q4 2024 Earnings Call Transcript - The Motley Fool

Ocugen (OCGN) Q4 2024 Earnings Call Transcript  The Motley Fool

Ocugen (OCGN) Q4 2024 Earnings Call Transcript - The Motley Fool

Click here to get full coverage on Ocugen (NASDAQ:OCGN shareholders incur further losses as stock declines 12% this week, taking three-year losses to 82% - simplywall.st

Ocugen (NASDAQ:OCGN shareholders incur further losses as stock declines 12% this week, taking three-year losses to 82%  simplywall.st

Ocugen (NASDAQ:OCGN shareholders incur further losses as stock declines 12% this week, taking three-year losses to 82% - simplywall.st

Click here to get full coverage on FDA Backs Ocugen's Revolutionary Gene Therapy for Rare Childhood Blindness - No Current Treatment Exists - Stock Titan

FDA Backs Ocugen's Revolutionary Gene Therapy for Rare Childhood Blindness - No Current Treatment Exists  Stock Titan

FDA Backs Ocugen's Revolutionary Gene Therapy for Rare Childhood Blindness - No Current Treatment Exists - Stock Titan

Click here to get full coverage on Ocugen (OCGN) stock forecast: Awaiting regulatory approval – Photo: Shutterstock - Capital.com

Ocugen (OCGN) stock forecast: Awaiting regulatory approval – Photo: Shutterstock  Capital.com

Ocugen (OCGN) stock forecast: Awaiting regulatory approval – Photo: Shutterstock - Capital.com

Click here to get full coverage on Ocugen Earnings: Can This Gene Therapy Pioneer Turn Financial Corner in 2024? - Stock Titan

Ocugen Earnings: Can This Gene Therapy Pioneer Turn Financial Corner in 2024?  Stock Titan

Ocugen Earnings: Can This Gene Therapy Pioneer Turn Financial Corner in 2024? - Stock Titan

Click here to get full coverage on FDA Clears Ocugen's Revolutionary Inhaled COVID-19 Vaccine for Clinical Trials - Stock Titan

FDA Clears Ocugen's Revolutionary Inhaled COVID-19 Vaccine for Clinical Trials  Stock Titan

FDA Clears Ocugen's Revolutionary Inhaled COVID-19 Vaccine for Clinical Trials - Stock Titan

Click here to get full coverage on OCGN - Ocugen Inc Latest Stock News & Market Updates - Stock Titan

OCGN - Ocugen Inc Latest Stock News & Market Updates  Stock Titan

OCGN - Ocugen Inc Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha

Ocugen stock gains on licensing deal (OCGN:NASDAQ)  Seeking Alpha

Ocugen stock gains on licensing deal (OCGN:NASDAQ) - Seeking Alpha

Click here to get full coverage on Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha

Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit  Seeking Alpha

Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha

Click here to get full coverage on Ocugen's Stargardt Disease Treatment Shows 52% Slower Disease Progression in Early Trials - Stock Titan

Ocugen's Stargardt Disease Treatment Shows 52% Slower Disease Progression in Early Trials  Stock Titan

Ocugen's Stargardt Disease Treatment Shows 52% Slower Disease Progression in Early Trials - Stock Titan

Click here to get full coverage on Maxim Group Initiates Coverage of Ocugen (OCGN) with Buy Recommendation - Nasdaq

Maxim Group Initiates Coverage of Ocugen (OCGN) with Buy Recommendation  Nasdaq

Maxim Group Initiates Coverage of Ocugen (OCGN) with Buy Recommendation - Nasdaq

Click here to get full coverage on Ocugen (OCGN) Set to Release Q1 Earnings with Minimal Revenue Expectations - GuruFocus

Ocugen (OCGN) Set to Release Q1 Earnings with Minimal Revenue Expectations  GuruFocus

Ocugen (OCGN) Set to Release Q1 Earnings with Minimal Revenue Expectations - GuruFocus

Click here to get full coverage on Ocugen (OCGN) Gains Rare Pediatric Disease Status for Eye Therapy - GuruFocus

Ocugen (OCGN) Gains Rare Pediatric Disease Status for Eye Therapy  GuruFocus

Ocugen (OCGN) Gains Rare Pediatric Disease Status for Eye Therapy - GuruFocus

Click here to get full coverage on Grabar Law Office Is Investigating Claims On Behalf Of - GlobeNewswire

Grabar Law Office Is Investigating Claims On Behalf Of  GlobeNewswire

Grabar Law Office Is Investigating Claims On Behalf Of - GlobeNewswire

Click here to get full coverage on Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results - Ocugen

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results  Ocugen

Ocugen to Host Conference Call on Wednesday, March 5, 2025 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2024 Financial Results - Ocugen

Click here to get full coverage on Revolutionary One-Time Gene Therapy Outperforms Monthly Injections in Macular Degeneration Trial - Stock Titan

Revolutionary One-Time Gene Therapy Outperforms Monthly Injections in Macular Degeneration Trial  Stock Titan

Revolutionary One-Time Gene Therapy Outperforms Monthly Injections in Macular Degeneration Trial - Stock Titan

Click here to get full coverage on These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Yahoo Finance

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar  Yahoo Finance

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar - Yahoo Finance

Click here to get full coverage on FDA grants Ocugen’s OCU410ST rare pediatric disease status - Investing.com

FDA grants Ocugen’s OCU410ST rare pediatric disease status  Investing.com

FDA grants Ocugen’s OCU410ST rare pediatric disease status - Investing.com

Click here to get full coverage on Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Ocugen

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit  Ocugen

Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Ocugen

Click here to get full coverage on NASDAQ: OCGN Investor Notice: Update in Lawsuit for Investors Who Lost Money With Ocugen, Inc. Shares Announced by the Shareholders Foundation - Newswire :) Press Release Distribution

NASDAQ: OCGN Investor Notice: Update in Lawsuit for Investors Who Lost Money With Ocugen, Inc. Shares Announced by the Shareholders Foundation  Newswire :) Press Release Distribution

NASDAQ: OCGN Investor Notice: Update in Lawsuit for Investors Who Lost Money With Ocugen, Inc. Shares Announced by the Shareholders Foundation - Newswire :) Press Release Distribution

Click here to get full coverage on Ocugen (OCGN) Receives FDA Clearance for Key Gene Therapy Trial | OCGN Stock News - GuruFocus

Ocugen (OCGN) Receives FDA Clearance for Key Gene Therapy Trial | OCGN Stock News  GuruFocus

Ocugen (OCGN) Receives FDA Clearance for Key Gene Therapy Trial | OCGN Stock News - GuruFocus

Click here to get full coverage on Ocugen To Present at BIO International Convention 2025 - GlobeNewswire

Ocugen To Present at BIO International Convention 2025  GlobeNewswire

Ocugen To Present at BIO International Convention 2025 - GlobeNewswire

Click here to get full coverage on Ocugen's Gene Therapy Shows 100% Success Rate in 2-Year Vision Loss Treatment Trial - Stock Titan

Ocugen's Gene Therapy Shows 100% Success Rate in 2-Year Vision Loss Treatment Trial  Stock Titan

Ocugen's Gene Therapy Shows 100% Success Rate in 2-Year Vision Loss Treatment Trial - Stock Titan

Click here to get full coverage on OCGN Gains as FDA Approves Trial for Stargardt Disease Therapy - GuruFocus

OCGN Gains as FDA Approves Trial for Stargardt Disease Therapy  GuruFocus

OCGN Gains as FDA Approves Trial for Stargardt Disease Therapy - GuruFocus

Click here to get full coverage on Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea | OCGN Stock News - GuruFocus

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea | OCGN Stock News  GuruFocus

Ocugen (OCGN) Secures Licensing Deal for Gene Therapy in Korea | OCGN Stock News - GuruFocus

Click here to get full coverage on Ocugen to Present at Eyecelerator Conference May 2025 - TipRanks

Ocugen to Present at Eyecelerator Conference May 2025  TipRanks

Ocugen to Present at Eyecelerator Conference May 2025 - TipRanks

Click here to get full coverage on IMMINENT OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire

IMMINENT OCGN DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Ocugen, Inc. Investors to Join the Class Action Lawsuit!  ACCESS Newswire

Ocugen Inc (OCGN)

Price Chart

Key Statistics

Technicals

About OCGN

Latest News

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of SPCE, OCGN and CRMD - ACCESS Newswire

Chardan Capital Maintains Buy Rating for Ocugen (OCGN) | OCGN St - GuruFocus

Carisma Therapeutics and OrthoCellix Enter into Definitive - GlobeNewswire

Advanced Charts

Top Gainers

Top Losers